JPRN-jRCT2031210574招募中3 期
A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
Inoue Tomoyoshi0 个研究点目标入组 22 人开始时间: 2022年1月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1. Previously participated in prior clinical study CC-93538-EE-001 and either:
- •a. completed both the Induction and Maintenance phases
- •b. completed the Induction Phase, however, did not qualify for the Maintenance Phase, including having a severe eosinophilic esophagitis (EoE) flare requiring endoscopic intervention or rescue therapy
- •2. Demonstrated compliance with required investigational product dosing during the prior study
- •3. Did not permanently discontinue investigational product in the prior study and/or did not experience any clinically significant adverse events related to Investigational Product that would preclude further dosing
- •4. Females of childbearing potential must have a negative pregnancy test prior to the first dose of open-label CC-93538 and agree to practice a highly effective method of contraception (as defined in the prior study) until 5 months after the last dose of open-label CC-93538
排除标准
- •1. Clinical or endoscopic evidence of other diseases or conditions that may affect or confound the histologic, endoscopic, or clinical symptom evaluation for this study.
- •2. Active Helicobacter pylori infection or esophageal varices.
- •3. Evidence of immunosuppression, or of having received systemic immunosuppressive or immunomodulating drugs within 5 drug half-lives prior to open-label extension study (OLE) Day 1. Use of these agents is prohibited during the study.
- •4. Treatment with oral or sublingual immunotherapy within 6 months of OLE Day 1. Use of these agents is prohibited during the study.
- •5. Received an investigational product, other than that administered in CC-93538-EE-001, within 5 half-lives prior to OLE Day 1 (includes investigational product received during an interventional trial for COVID-19). Those vaccinated with an investigational COVID-19 vaccine during CC-93538-EE-001 are not eligible, unless allowed following a discussion with the Clinical Trial Physician.
- •6. Received a live attenuated vaccine within one month prior to OLE Day 1; or anticipates the need for a live attenuated vaccine at any time throughout the course of this study.
- •7. Any disease that would affect the conduct of the protocol or interpretation of the study results, or would put a patient at risk by participating in the study (e.g. colitis, celiac disease, Mendelian disorder associated with EoE, severe uncontrolled asthma, infection causing eosinophilia, hypereosinophilic syndrome, or cardiovascular condition, or neurologic or psychiatric illness that could compromise the participant's ability to accurately document symptoms of EoE; newly diagnosed malignancy, lymphoproliferative disease, or clinically significant laboratory abnormality).
- •8. Active or ongoing infections including parasitic/helminthic infections, viral hepatitis, tuberculosis, or HIV.
- •9. Has had idiopathic anaphylaxis or major immunologic reaction to an immunoglobulin-G containing agent; or any known hypersensitivity to any ingredient in CC-93538.
- •10. Females who are pregnant or lactating.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitisEOSINOPHILIC ESOPHAGITISMedDRA version: 20.1Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 100000004856EUCTR2020-004335-24-ESCelgene International II Sàrl259
进行中（未招募）
1 期
A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitisMedDRA version: 20.1Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersEOSINOPHILIC ESOPHAGITISEUCTR2020-004335-24-PLCelgene International II Sàrl269
进行中（未招募）
1 期
A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitisMedDRA version: 20.1Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 100000004856EOSINOPHILIC ESOPHAGITISEUCTR2020-004335-24-PTCelgene International II Sàrl269
进行中（未招募）
1 期
A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitisEOSINOPHILIC ESOPHAGITISEUCTR2020-004335-24-DECelgene International II Sàrl269
进行中（未招募）
1 期
A study to evaluate the long-term safety of CC-93538 in adult and adolescent patients who have eosinophilic esophagitisEOSINOPHILIC ESOPHAGITISEUCTR2020-004335-24-BECelgene International II Sàrl269